

2025

(Pharmacy)

GNIPST BULLETIN

Volume-3, Issue- 6



GURU NANAK INSTITUTE OF PHARMACEUTICAL
SCIENCE AND TECHNOLOGY


157/F, Nilgunj Road, Kolkata- 700114, West Bengal, India



Table of Contents

- 01 Message from Director and Principal**
- 02 Recent Researches**
- 03 New Drug Approvals**
- 04 Clinical Trial News**
- 05 Disease Outbreak News**
- 06 Campus News**
- 07 Special Page and Game time**





MESSAGE FROM HONORABLE DIRECTOR

As the Director of Guru Nanak Institute of Pharmaceutical Science and Technology, I extend my heartfelt greetings and warm wishes to all our students, faculty, staff, alumni, and well-wishers on the joyous occasion of Christmas Day 2025.

Christmas is a celebration of love, peace, compassion, and togetherness. It reminds us of the timeless values of kindness, generosity, humility, and service to humanity. This sacred occasion encourages us to reflect on the true spirit of giving, forgiveness, and unity, which are essential for

building a harmonious and inclusive society.

At GNIPST, we believe that nurturing young minds with knowledge, ethics, empathy, and social responsibility is central to our educational mission. The spirit of Christmas resonates deeply with our commitment to holistic education—one that not only imparts academic excellence but also instills moral values and a sense of purpose in our students.

As educators and mentors, let us continue to inspire our students to lead with integrity, think innovatively, and serve society with compassion. May this festive season strengthen our collective resolve to create a positive learning environment filled with hope, mutual respect, and excellence.

On this special day, let us celebrate togetherness and renew our dedication to shaping responsible professionals and conscientious citizens.

Wishing you all a Merry Christmas 2025.

Prof. (Dr.) Abhijit Sengupta



MESSAGE FROM HONORABLE PRINCIPAL

I extend my warm greetings and best wishes to our students, faculty, staff, alumni, and valued partners on the joyous occasion of Christmas Day 2025. This blessed festival symbolizes love, peace, compassion, and the spirit of giving, reminding us of the enduring values that bind humanity together.

Christmas invites us to reflect on kindness, humility, and service to others. It encourages us to share joy, spread hope, and strengthen the bonds of unity and understanding within our academic community and beyond.

At Guru Nanak Institute of Pharmaceutical Science and Technology (GNIPST), we believe that education is the most meaningful gift we can offer to society—one that enlightens minds, nurtures character, and empowers individuals to contribute positively to the world. Since our inception in 2005, GNIPST has grown into a distinguished centre of pharmaceutical education, recognized by the Pharmacy Council of India (PCI), proudly holding both NAAC and NBA accreditations, and achieving the 85th rank in NIRF 2025, reflecting our steadfast commitment to excellence and continuous progress. On this auspicious day, let us reaffirm our collective responsibility to guide and inspire our students, fostering an environment that promotes academic excellence, ethical values, innovation, and holistic development. Together, let us continue to build a vibrant learning community rooted in mutual respect, empathy, and shared purpose.

Wishing everyone a Merry Christmas 2025.



Prof. (Dr.) Lopamudra Datta





RECENT RESEARCHES



key outcomes and priority actions for global immunization

MORE INFO

www.who.int/

The September 2025 meeting of the Strategic Advisory Group of Experts on Immunization (SAGE), held from 22–25 September with a joint session with the Malaria Policy Advisory Group (MPAG), brought renewed focus to both the progress and persistent challenges facing global immunization. While vaccination coverage worldwide has largely rebounded to pre-pandemic levels, recovery remains uneven — particularly in fragile and conflict-affected settings. Funding constraints, geopolitical instability, and an ongoing erosion of public trust continue to threaten vaccine acceptance and uptake. SAGE's mid-term review of the Immunization Agenda 2030 (IA2030) reaffirmed the relevance of its vision, but calls for accelerated action and stronger partnerships to help countries integrate immunization into primary health care and strengthen data use for driving and implementing programme strategies.

WHO and Bayer AG renew longstanding collaboration to eliminate three deadly neglected tropical diseases

MORE INFO

www.who.int/

The World Health Organization (WHO) and the German pharmaceutical company, Bayer AG, have renewed a longstanding collaboration to support endemic countries in scaling up free-of-charge treatment against three deadly neglected tropical diseases (NTDs). Since 2002, Bayer AG has been donating medicines in support of WHO's work on NTDs, which is now managed by the newly-established Department of Malaria and Neglected Tropical Diseases (MNT). The five-year extension (2025–2030) continues previous engagements, covering both the donation of quality-assured medicines and the provision of financial support to global programmes against Chagas disease (American trypanosomiasis), human African trypanosomiasis (sleeping sickness) and taeniasis/cysticercosis (pork tapeworm disease).

WHO releases policy brief on priority setting in TB programme planning

MORE INFO

www.who.int/

The World Health Organization (WHO) has released a [new policy brief](#) to support national TB programmes in setting priorities and allocating resources based on strategic, evidence-informed and people-centred approaches aimed at accelerating progress towards ending the TB epidemic. The brief introduces a structured approach to priority setting, emphasizing transparency, inclusion, evidence-based decision-making, and accountability as key principles for effective and equitable TB programme planning. The new brief also outlines strategies to mitigate the impact of unexpected funding shortfalls, including improving efficiency, integrating TB care within primary health care-oriented health systems, and safeguarding high-impact, life-saving interventions.

FDA



NEW DRUG APPROVALS

November, 2025

Kygevvi (doxycitine and doxributimine) Powder for Oral Solution

- Date of Approval: November 3, 2025
- Company: UCB
- Treatment for: Thymidine Kinase 2 Deficiency



Redemplo (plozasiran) Injection

- Date of Approval: November 18, 2025
- Company: Arrowhead Pharmaceuticals, Inc.
- Treatment for: Familial Chylomicronemia Syndrome



Itivima (onasemnogene abeparvovec-brve) Suspension for Intrathecal Injection

- Date of Approval: November 24, 2025
- Company: Novartis
- Treatment for: Spinal Muscular Atrophy



Komzifti (ziftomenib) Capsules

- Date of Approval: November 13, 2025
- Company: Kura Oncology, Inc.
- Treatment for: Acute Myeloid Leukemia



Hyrnuo (sevabertinib) Tablets

- Date of Approval: November 19, 2025
- Company: Bayer
- Treatment for: Non Small Cell Lung Cancer



Armlupeg (pegfilgrastim-unne) Injection

- Date of Approval: November 28, 2025
- Company: Lupin Limited
- Treatment for: Neutropenia Associated with Chemotherapy, Neutropenia Associated with Radiation



Vyxact (sibeprenlimab-szsi) Injection

- Date of Approval: November 25, 2025
- Company: Otsuka Pharmaceutical Co., Ltd.
- Treatment for: Immunoglobulin A Nephropathy


<https://www.drugs.com/newdrugs-archive/2025.html>

CLINICAL TRIAL NEWS

**01.**

New Phase 3 Data Show Takeda's Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization

OSAKA, Japan and CAMBRIDGE, Massachusetts, November 3, 2025 – Takeda (TSE:4502/NYSE:TAK) announced the completion of the 7-year pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial evaluating its dengue vaccine, QDENGA®(Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003). These data, including an exploratory analysis of a booster dose, confirm the favorable benefit and risk profile of QDENGA and that the two-dose regimen provides sustained protection against dengue.

02.

Novo Nordisk Presents Four New Analyses on Oral Semaglutide 25 mg (Wegovy® in a Pill) at ObesityWeek® 2025

Plainsboro, NJ and Bagsværd, Denmark, 5 November, 2025 – Novo Nordisk today presented new data from the OASIS 4 phase 3 trial that explored a variety of patients and hypotheses, adding to the body of evidence supporting this potential treatment option. Four abstracts in total were presented, highlighting a breadth of results with oral semaglutide 25 mg during ObesityWeek® 2025 in Atlanta, GA.

03.

Novo Nordisk's CagriSema Associated with Significant Reduction in Blood Pressure and Showed Anti-Inflammatory Effects While Reducing the Proportion of Patients at Risk of Developing Heart Disease Over Time

Plainsboro, NJ and Bagsværd, Denmark, November 6, 2025 – At Obesity Week® (November 4-7 in Atlanta, GA), Novo Nordisk presented new post hoc analyses from the phase 3 REDEFINE 1 trial evaluating CagriSema, an investigational injectable combination treatment for adults with overweight or obesity, and its effects on well-known cardiovascular (CV) risk factors, including hypertension and systemic inflammation.

04.

Neurogastrx Announces NG101 Phase 2 Clinical Study Demonstrating Significant Reductions in Nausea and Vomiting Induced by GLP-1 Receptor Agonist Semaglutide

WOBURN, MA, November 7, 2025 – Neurogastrx, Inc., today presented proof-of-concept data from its placebo-controlled Phase 2 clinical study of NG101 (metopimazine mesylate), an oral, peripherally restricted dopamine D₂ receptor antagonist for the treatment of GLP-1-induced nausea and vomiting. These data, shared in an oral presentation at Obesity.

05.

Novo Nordisk's Wegovy (semaglutide 2.4 mg) Was Associated with Liver Health-Related Benefits Not Solely Based on Weight Loss in Adult Patients with MASH with Liver Scarring

Plainsboro, NJ, US and Bagsværd, Denmark, 10 November 2025 – Novo Nordisk today presented data at the 76th annual American Association for the Study of Liver Diseases (AASLD) meeting, The Liver Meeting® 2025, in Washington, D.C., evaluating the effects of semaglutide 2.4 mg in people with metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-advanced liver scarring (fibrosis).

06.

Evoke Phase 3 Oral Semaglutide Trials Did Not Demonstrate a Statistically Significant Reduction in Alzheimer's Disease Progression

Bagsværd, Denmark, 24 November 2025 – Novo Nordisk today announced the top-line results from the 2-year primary analysis of evoke and evoke+ phase 3 trials in early-stage symptomatic Alzheimer's disease. The two trials were randomised, double-blinded, enrolled a total of 3808 adults and evaluated the efficacy and safety of oral semaglutide compared to placebo on top of standard of care. The decision to pursue an Alzheimer's disease indication with semaglutide was based on real-world evidence studies, pre-clinical models as well as post-hoc analyses from diabetes and obesity trials.

07.

Novo Nordisk Phase 2 Trial with Amycretin Reports Significant Weight Loss and HbA1c Reduction in Type 2 Diabetes

Bagsværd, Denmark, 25 November 2025 – Novo Nordisk today announced positive headline results from a phase 2 clinical trial with amycretin in people with type 2 diabetes. This marks the first evaluation of amycretin in people with type 2 diabetes, further demonstrating Novo Nordisk's commitment to advancing innovation in the treatment of type 2 diabetes. Amycretin is a unimolecular agonist of the glucagon-like peptide 1 (GLP-1) and amylin receptors, intended for once-weekly subcutaneous administration and once-daily oral administration.

MORE INFORMATIONhttps://www.drugs.com/clinical_trials_archive/november-2025.html



DISEASE OUTBREAK NEWS (DONS)

December, 2025

Ebola virus disease - Democratic Republic of the Congo

1 December 2025

Situation at a glance

On 1 December 2025, the Ministry of Health (MoH) of the Democratic Republic of the Congo (DRC) declared the end of the Ebola virus disease (EVD) outbreak which had been declared on 4 September 2025. The end was declared after two consecutive incubation periods (a total of 42 days) since the last person confirmed with EVD tested negative for the virus and was discharged on 19 October 2025. A total of 64 cases (53 confirmed, 11 probable), including 45 deaths (CFR 70.3%), were reported from six health areas in Bulape Health Zone, Kasai Province. WHO and partners provided technical, operational and financial support to the government to contain the outbreak. This is the country's 16th outbreak of Ebola. Although the outbreak has been declared over, health authorities are maintaining surveillance to rapidly identify and respond to any re-emergence. Risk communication and community engagement activities will continue to provide accurate information, monitor and address community feedback and rumours, and support efforts to reduce stigma toward individuals affected by the outbreak.

MORE INFO

<https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON573>




Broader transmission of mpox due to clade Ib MPXV – Global situation

5 December 2025

Situation at a glance

The purpose of this report is to raise awareness about the local transmission of clade Ib monkeypox virus (MPXV) among men who have sex with men (MSM) in countries previously unaffected or to date reporting only cases linked to travel. This report summarizes recent epidemiological developments, response activities, and the associated global public health risk. The second declaration of a public health emergency of international concern (PHEIC) for mpox was lifted on 5 September 2025. As both MPXV clades I and II and their subclades continue to circulate globally, leading to substantial outbreaks in African countries, WHO continues to advise emergency preparedness and response activities. Multiple modes of transmission underlie ongoing virus circulation, with sexual contact remaining the primary amplifier of transmission in most settings. Since 5 September 2025, several countries across four of six WHO regions have confirmed clade Ib MPXV infection in individuals with no recent travel reported (WHO African Region, Region of the Americas, the European Region and the Western Pacific Region), most of which are being detected among men who have sex with men, suggesting local transmission, particularly given that infections often manifest with few or no symptoms (paucisymptomatic or asymptomatic cases) leading to undetected onward transmission. Overall, the surveillance data in most countries is sufficient to detect and respond effectively to mpox outbreaks.



MORE INFO

<https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON566>

Merry Christmas


Christmas, celebrated on 25th December, is one of the most joyous and widely celebrated festivals around the world. It marks the birth of Lord Jesus Christ, symbolizing love, peace, and hope for humanity. The festival fills homes and hearts with warmth, happiness, and the spirit of giving. Streets, churches, and homes are beautifully decorated with lights, Christmas trees, and nativity scenes, creating a magical atmosphere that unites people of all ages and communities.

- Celebrates the birth of Jesus Christ, spreading the message of love, compassion, and forgiveness.
- Encourages generosity and kindness, inspiring people to share joy through gifts and charity.
- Strengthens family bonds as loved ones gather to celebrate together.
- Brings communities together through prayers, carols, and festive activities.
- Promotes hope, peace, and harmony across cultures and nations.

Christmas reminds everyone to embrace love, spread joy, and keep the spirit of giving alive all year round.




GNIPST GAME TIME



Puzzle

- The letters from each cell are below the puzzle.
- Try to rebuild the original message by choosing the letters for each cell.



P	O
M F C A D T E R S E D N	
F E I S H T P I S T E Y E C S N I O A R	
L I Q U F D E C E L V E S I A N T S I L S E L F D S A G E	

Stay tuned for to the next edition for a shout out to fastest correct answers!

Submit your answer



or

**CLICK
HERE**

Celebrating the Achievers!



Debanjan Bhattacharya

B. Pharm, 5th Semester

Guru Nanak Institute of Pharmaceutical Science and Technology

Editorial Board

Editor- in- Chief

Prof. (Dr.) Abhijit Sengupta

Managing Editors

Prof. (Dr.) Lopamura Datta

Associate Editors

Mr. Tushar Adhikari

Ms. Manjarima Ganguli

Editorial Board Members

Mrs. Indrani Banerjee Chakraborty

Mr. Arpan Dutta

Ms. Parnasree Chakraborty

Ms. Lopamudra Saha

Mr. Sarthak Saha



COURSES OFFERED

PHARMACY UG COURSES

- Bachelor of Pharmacy (B.Pharm)

PHARMACY DIPLOMA COURSES

- Diploma in Pharmacy (D.Pharm)

PHARMACY PG COURSES

- M.Pharm in Pharmaceutics
- M.Pharm in Pharmacology
- M.Pharm in Pharmaceutical Chemistry
- M.Pharm in Quality assurance
- M.Pharm in Regulatory Affairs
- M.Pharm in Pharmacognosy
- M.Pharm in Pharmaceutical Biotechnology

Major
Recruiters

Cipla
RnD SOLUTIONS

ZIFO
Cognizant

Nestle

wipro
TRIMPLIN

IQVIA

MACLEODS

FRESENIUS KABI

tcs

**Latest
news**



www.gnipst.ac.in



www.facebook.com



www.instagram.com



www.linkedin.com



www.youtube.com



api.whatsapp.com